---
title: "361 Product Marketing: 7 Clear Rules for HCT/P Companies"
description: "Seven rules for 361 product marketing: match the 1271.10 criteria, keep registered from implying approved, and stop treatment claims before clinics copy them."
url: "https://regenportal.com/361-product-marketing-hctp-companies/"
---

# 361 Product Marketing: 7 Clear Rules for HCT/P Companies

- [Oscar Tellez](https://regenportal.com/oscar-tellez/)
- Published October 13, 2026

![361 product marketing as a walnut shelf of blank black archive boxes, one recess backlit green](https://regenportal.com/wp-content/uploads/2026/09/361-product-marketing-hctp-companies.png)

Your product is a 361 HCT/P, and 361 product marketing has one job: describe the product exactly as the rule describes it. Every deck, label, product page, and rep script has to fit inside that description. This post gives the owner or marketing lead of a cell or tissue product company seven rules that keep marketing and regulatory status in the same place.

**TLDR:** Marketing that goes past the four criteria in 21 CFR 1271.10 is evidence the product is intended for a use 361 does not cover. Your homologous use language has to match your listing. “Registered” and “listed” never mean “approved” in 361 product marketing. No disease, treatment, or outcome claim survives in any channel, including a rep’s mouth. Keep the claim sheet and the labeling in one file. Read on for the seven rules, the mistakes we flag most, and a scenario built around one borrowed word on one slide.

**Important Note**

This article is for educational purposes only and does not constitute legal, medical, or regulatory advice. Marketing strategies discussed should be reviewed by qualified legal counsel before implementation, particularly regarding FDA, FTC, and state-specific advertising regulations. Regen Portal is a marketing and consulting company, not a law firm. Nothing here implies FDA approval of any product or any use. Most cell, tissue and exosome products marketed to patients are not FDA approved, and the few cell-based products the FDA has approved are approved only for specific labeled indications. Nothing here promises a marketing or business outcome. Regulations change and enforcement varies by state. Confirm current requirements with qualified legal and compliance counsel before you act on anything you read here.

When a product company hands us a deck, a one-pager, or a website to review, the same three things get flagged first. Non-compliant claims. Wording too complex for the buyer. Weak graphics. The first is the expensive one, and it almost never comes from the regulatory team.

It comes from the deck. Sales wanted slide 7 to sound stronger. The web team wanted the product page to rank. Each change was small. Together they described a different product than the one on the listing.

This post gives you seven rules that stop that drift. They rest on one idea: in 361 product marketing, the marketing is part of the product’s status, not something beside it.

## What 361 Product Marketing Means for a Product Company

For a clinic, 361 versus 351 is about what it may say on a service page. For you, it is about what your product is. Your marketing is evidence of whether the product meets the criteria.

Section 361 of the Public Health Service Act covers HCT/Ps that meet four criteria in 21 CFR 1271.10. A product that meets all four sits under Part 1271 alone. A product that misses any one of them moves toward the drug, device, or biologic path. Counsel decides which side of that line your product sits on, and your marketing is part of what counsel reads.

We have worked with dozens of manufacturers and distributors on consulting and marketing, and the pattern is steady. The regulatory file describes one product. The deck describes a bigger one. The website describes a bigger one still. Nobody meant to write three. The reader sees the biggest.

The seven rules below keep those three documents describing the same thing.

## Rules 1 and 2: The Four Criteria Describe Your Product

Rule 1 is that the four criteria describe your product and its intended use, and your marketing must match them. They are not a checklist you pass once. They apply to the product as sold today.

Here is the short version, from [21 CFR 1271.10](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271/subpart-A/section-1271.10). The HCT/P must be “minimally manipulated” in the rule’s words. It must be “intended for homologous use only, as reflected by the labeling, advertising, or other indications of the manufacturer’s objective intent” as well.

The third criterion limits what may be combined with the tissue to “water, crystalloids, or a sterilizing, preserving, or storage agent” only. The fourth covers systemic effect and living cells. Either the product has no systemic effect and does not rely on living cells, or it does and its use is limited. The limits are autologous use, a first- or second-degree blood relative, or reproductive use.

Read the second criterion again. The rule itself names labeling and advertising as evidence of the maker’s intent. Your deck, your product page, and your booth banner are all advertising.

Rule 2 follows: your homologous use language must match your listing. Homologous use is defined in [21 CFR 1271.3](https://www.ecfr.gov/current/title-21/chapter-I/subchapter-L/part-1271/subpart-A/section-1271.3). It turns on whether the cells or tissue do the same basic job in the recipient as in the donor. FDA’s July 2020 guidance on minimal manipulation and homologous use, [Regulatory Considerations for HCT/Ps](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/regulatory-considerations-human-cells-tissues-and-cellular-and-tissue-based-products-minimal), explains how the agency reads both criteria. Your counsel will use it, so your marketing team should read it too.

In practice, if the listing describes a structural or covering use, the deck may not describe a use that depends on something else. The clinic-facing version sits in the [361 versus 351 distinction](https://regenportal.com/361-vs-351-what-every-regen-clinic-marketer-needs/), and it helps to know what your buyers have read.

Once the product description is locked, the next two rules deal with the words companies reach for to sound bigger.

## Rules 3 and 4: Registered Is Not Approved, and No Treatment Claims

Rule 3 is that “registered” and “listed” may never be used to imply approval. Rule 4 is that no disease, treatment, or outcome claim appears in any channel. Both exist because official-sounding words make a reader hear more than they say.

Start with registration. A 361 HCT/P maker must register with FDA and list each product, with an update each December, per the [tissue establishment registration page](https://www.fda.gov/vaccines-blood-biologics/biologics-establishment-registration/tissue-establishment-registration). The same page says FDA acceptance of a registration and listing does not mean the firm is in compliance. It also does not mean the HCT/P “is licensed or approved by FDA” in the page’s own words. Registration is a filing, not a review.

So “FDA registered” may appear on your site as a plain fact, next to what it means. It may not appear as a badge or a headline, and never beside “approved” or “safe” where a reader can blend them. “FDA registered clinic” is the credential claim we see most often on regen sites. Clinics learned it somewhere, and often the source was a supplier’s deck.

Now the treatment claim. The moment a deck says the product “treats” or “repairs” a named condition, it is describing an intended use. That use may not be the homologous one on your listing. It is also a claim about effect that no premarket review has checked. Neither problem is fixed by an asterisk.

This rule has no channel exception. It covers the label, the insert, the website, the deck, and the rep’s hallway pitch. The [distributor compliance rules](https://regenportal.com/distributor-compliance-biologics-reps/) cover the rep side in depth, but what the rep says usually starts in your material.

With the big two claims handled, the last three rules are about discipline.

## Rules 5 to 7: Sober Research, the Downstream Clinic, and One File

Rule 5 is that research language stays sober and specific. Rule 6 is that the clinic’s ads are downstream of your deck. Rule 7 is that the claim sheet and the labeling live in one file. These keep the first four from drifting.

Research first. A 361 product company may discuss published science, but how it does so is a claim in itself. “Studies show it works” is a claim. A sentence that names the study type, what was measured, and what was never tested is a description. Never let a lab finding stand in for a clinical effect. One more limit. Research on a use outside your product’s homologous use can be read as proof of intended use, even when every sentence is hedged. Keep white papers, viability studies, cell counts, and mechanism language out of decks and product pages unless counsel clears them.

Now the downstream rule. Reps routinely say things to clinic owners that are not FDA compliant, and in this industry that gets treated as normal. We have watched that language travel from the rep’s pitch into the clinic’s own ads and marketing, sometimes word for word, superlatives included. The clinic did not invent the sentence. It copied your slide, and your product name is in the ad.

That is why the deck is the most important compliance document in 361 product marketing. The clinic trusts it more than the insert. To see what the clinic wants to write, read how clinics build [exosome service pages](https://regenportal.com/write-exosome-service-pages-that-dont-trigger-fda/) that stay inside the line. Your deck either helps them or makes it impossible.

Rule 7 is the working fix. Keep one file with the label text, the listing description, and the approved claim sheet. The labeling rule says each HCT/P made available for distribution must be labeled “clearly and accurately” per 21 CFR 1271.370. The same section lists what must appear on the label or come with the product. When a marketer writes a new slide, the sentence has to trace to a line in that file. If it cannot, it does not ship.

The rules are simple to state. Here is where companies break them without noticing.

## Common Mistakes in Decks and Product Pages

The most common mistake in 361 product marketing is not a wild claim. It is a small word that changes the intended use, placed where nobody reviews it. Here are the ones we flag most.

The first is the subheading claim. The body copy is careful. The slide title says “Regenerative Support for Joints” and nobody reads it as a claim. Titles get written last and reviewed least. Read them as if they were the only text on the page, because for many readers they are.

The second is “minimally manipulated” used as a selling point. It is a criterion, not a feature, and it tells a buyer nothing about what the product does. We covered why [minimally manipulated fails as strategy](https://regenportal.com/why-minimally-manipulated-is-not-marketing-strat/) from the clinic side, and the same holds on yours.

The third is the borrowed comparison. A product page says the product “offers the benefits of stem cell therapy” at a lower price. That is a treatment claim for two products at once, one of which is not yours. Exosome products carry the same trap, and the rules for [exosome marketing claims](https://regenportal.com/exosome-marketing-in-2026-what-you-can-say/) show how narrow the safe lane is.

The fourth is the testimonial slide. A physician quote saying “my patients love the results” is an outcome claim with endorsement rules on top.

One more deserves its own section: the slide that borrows a treatment word from a different product category.

## A Scenario: The Slide That Borrowed a Treatment Word

Picture a birth tissue product company whose listing describes a covering and structural use. The regulatory file is clean. The label meets the rule. The deck was built by a sales lead from the device side, where an indication sits on every slide.

Slide 7 carried the headline “Indicated for the Treatment of Chronic Tendon Injuries” across the top. Nobody on the regulatory team saw the deck. “Indicated” came from the sales lead’s old habits. “Treatment” came from a competitor’s brochure. The condition came from what customers kept asking about.

Reps used the deck for a season. Two clinics copied the headline into a service page. One turned it into a paid ad. Now the product name sits beside a treatment claim for a named condition, in a channel the company never touched. Its own slide is the source.

The fix has an order. Pull the deck. Replace the headline with the listing language. Reissue it to every rep with a note that explains why. Write to the two clinics with the corrected language. Then build the one file from Rule 7. Whether the old slide changed the product’s status is a question for counsel. The marketing side is the part you control today.

These are the questions product companies ask us most.

## Frequently Asked Questions

### Can a 361 Product Company Say It Is FDA Registered?

It may state the fact plainly, and it may not use it to imply approval. FDA’s own registration page says acceptance of a registration and listing does not mean the product is licensed or approved. Write the fact in a sentence, next to what it means, and keep it out of headlines and badges.

### Does a Label That Meets 1271.370 Make the Marketing Compliant?

No. The labeling rule sets what must appear on or with the product. The 1271.10 criteria read the labeling and the advertising together as evidence of intended use. A perfect label under a deck that claims a treatment effect still leaves a marketing problem. Both need to describe the same product.

### Can We Cite Published Studies in a Product Deck?

Sometimes, and counsel decides. The study must be described accurately, with its limits stated, and it must match your product’s listed use. Say what kind of study it was, what it measured, and what it did not test. Do not let a lab finding stand in for a clinical result. Counsel should review the research slides.

### What if a Clinic Makes a Claim We Never Made?

The clinic owns its ads, but your product name is in them, and someone will ask where the sentence started. Keep a record of the materials you issued and the claim file behind them. If a clinic goes beyond your material, write to them with the corrected language. Your record helps show where the claim came from.

### Who Decides Whether Our Use Is Homologous?

Your regulatory counsel, using the definition in 21 CFR 1271.3 and FDA’s July 2020 guidance on minimal manipulation and homologous use. Marketing does not decide it, but marketing can undo it, because the rule reads advertising as evidence of intended use. So the deck goes to counsel before it goes to sales.

### How Often Should the Claim File Be Reviewed?

Every time the listing changes, whenever new marketing is built, and at least once a year with the registration update. A review also makes sense after a public enforcement action on a similar product or claim type. Counsel sets the schedule.

## Key Takeaways

- The four criteria in 21 CFR 1271.10 describe your product and its intended use, and your 361 product marketing must match them.
- The rule reads labeling and advertising as evidence of the maker’s intent, so every deck and product page counts.
- Your homologous use language must match your listing, and counsel decides what is homologous.
- “Registered” and “listed” are filings, and FDA’s own page says they do not mean approval.
- No disease, treatment, or outcome claim belongs in any channel, including the rep’s spoken pitch.
- Research language names the study type, what was measured, and what was never tested.
- The claim sheet, the listing description, and the label text live in one file, and every new sentence traces to it.

## Your Next Step

Good 361 product marketing is not quieter marketing. It describes the product you actually have, in words a clinic buyer can repeat without harm. That position survives the buyer’s review. A borrowed treatment word does not.

If you want a second set of eyes on the deck, the product page, or the claim file, that is where we start. Our [marketing compliance work](https://regenportal.com/marketing-compliance/) begins with a full inventory of what is live, each flagged phrase with its reason, and a lower-risk rewrite.

PS: Send us your current deck or product page and we will review it against these seven rules at no cost.

Email: [hello@regenportal.com](mailto:hello@regenportal.com)

YouTube: [Subscribe to the channel](https://www.youtube.com/@oatellez)

## About Regen Portal

Regen Portal is a marketing and consulting company built for the regenerative medicine industry. We handle practice consulting, marketing compliance, search engine optimization, content creation, social media management, paid advertising, website development, branding, and AI and ops consulting for clinics, manufacturers, distributors, and independent providers. For more on me and how we work, visit Regen Portal and [contact us](https://regenportal.com/contact-us/).

## About the Author

[Oscar Tellez](https://regenportal.com/oscar-tellez/) is the founder of Regen Portal, a marketing and consulting company built for the regenerative medicine industry. He has been in this industry since 2015. He started in medical sales and has worked with PRP since 2016. He has reached hundreds of practices and over 200 doctors through sales, teaching and marketing. He holds a B.S. in Exercise Science and Health Promotion from Florida Atlantic University.

[Add Regen Portal as a Preferred Source on Google](https://www.google.com/preferences/source?q=regenportal.com)

[PrevPreviousAfter-Hours Lead Handling: 5 Clear Rules for AI Assistants](https://regenportal.com/after-hours-lead-handling-ai-assistants/)

[NextRegen Practice Pricing: 6 Clear Ways to Package ConsultsNext](https://regenportal.com/regen-practice-pricing-consult-packages/)

## Table of Contents

### [Enforcement Watch October 2026: 7 Clear Company Lessons](https://regenportal.com/enforcement-watch-october-2026/)

October 20, 2026

### [Front Desk AI Policy: 7 Clear Rules Before Staff Use It](https://regenportal.com/front-desk-ai-policy-clinics/)

October 19, 2026

### [Peptide Marketing in 2026: 7 Clear Rules for Clinics](https://regenportal.com/peptide-marketing-2026-clinics/)

October 16, 2026

```json
{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/regenportal.com\/361-product-marketing-hctp-companies\/#article","mainEntityOfPage":"https:\/\/regenportal.com\/361-product-marketing-hctp-companies\/","headline":"361 Product Marketing: 7 Clear Rules for HCT\/P Companies","description":"Seven rules for 361 product marketing: match the 1271.10 criteria, keep registered from implying approved, and stop treatment claims before clinics copy them.","image":["https:\/\/regenportal.com\/wp-content\/uploads\/2026\/09\/361-product-marketing-hctp-companies.png"],"url":"https:\/\/regenportal.com\/361-product-marketing-hctp-companies\/","datePublished":"2026-10-13","dateModified":"2026-10-13","inLanguage":"en-US","articleSection":"Regulatory","author":{"@type":"Person","@id":"https:\/\/regenportal.com\/oscar-tellez\/#person","name":"Oscar Tellez","url":"https:\/\/regenportal.com\/oscar-tellez\/","image":{"@type":"ImageObject","url":"https:\/\/regenportal.com\/wp-content\/uploads\/2026\/05\/Oscar-Tellez-e1778268697402.png"},"jobTitle":"Founder","description":"I've been inside this industry since 2015. I help clinics, manufacturers, distributors and every other kind of business in this field grow, with consulting first and then marketing that follows the rules.","worksFor":{"@type":"MarketingAgency","@id":"https:\/\/regenportal.com\/#organization","name":"Regen Portal","url":"https:\/\/regenportal.com\/"},"knowsAbout":["Regenerative Medicine Marketing","Medical SEO","Cash-Based Practice Growth","Stem Cell Therapy Marketing","FDA\/FTC Healthcare Advertising Compliance","Brand Strategy for Medical Practices","Paid Advertising for Medical Practices"],"sameAs":["https:\/\/www.linkedin.com\/in\/o-tellez\/","https:\/\/www.instagram.com\/realoscartellez\/","https:\/\/www.youtube.com\/@oatellez"],"alumniOf":{"@type":"CollegeOrUniversity","name":"Florida Atlantic University"}},"publisher":{"@type":"MarketingAgency","@id":"https:\/\/regenportal.com\/#organization","name":"Regen Portal","url":"https:\/\/regenportal.com\/","logo":{"@type":"ImageObject","url":"https:\/\/regenportal.com\/wp-content\/uploads\/2025\/12\/Regen-Portal-Footer-Logo.png"}},"name":"361 Product Marketing: 7 Clear Rules for HCT\/P Companies"},{"@type":"Place","@id":"https:\/\/regenportal.com\/#place","geo":{"@type":"GeoCoordinates","latitude":"25.7469247","longitude":"-80.2593893"},"hasMap":"https:\/\/www.google.com\/maps\/search\/?api=1&query=25.7469247,-80.2593893","address":{"@type":"PostalAddress","addressLocality":"Miami","addressRegion":"Florida","addressCountry":"US","streetAddress":"226 ALMERIA AVE #1043","postalCode":"33134"}},{"@type":["Organization"],"@id":"https:\/\/regenportal.com\/#organization","name":"Regen Portal","url":"https:\/\/regenportal.com","sameAs":["https:\/\/www.facebook.com\/regenportal","https:\/\/linkedin.com\/company\/regen-portal\/","https:\/\/www.instagram.com\/regenportal\/","https:\/\/search.sunbiz.org\/Inquiry\/corporationsearch\/SearchResultDetail?inquirytype=EntityName&directionType=Initial&searchNameOrder=REGENPORTAL%20L250005352700&aggregateId=flal-l25000535270-3e485d68-27cf-42d4-aa19-e30d3a213661&searchTerm=REGENORTHORX%2C%20LLC&listNameOrder=REGENORTHORX%20L160000490770"],"email":"hello@regenportal.com","address":{"@type":"PostalAddress","addressLocality":"Miami","addressRegion":"Florida","addressCountry":"US","streetAddress":"226 ALMERIA AVE #1043","postalCode":"33134"},"logo":{"@type":"ImageObject","@id":"https:\/\/regenportal.com\/#logo","url":"https:\/\/regenportal.com\/wp-content\/uploads\/2025\/12\/foter-logo.png","contentUrl":"https:\/\/regenportal.com\/wp-content\/uploads\/2025\/12\/foter-logo.png","caption":"Regen Portal","inLanguage":"en-US","width":"464","height":"185"},"priceRange":"$$$","contactPoint":[{"@type":"ContactPoint","telephone":"+1 786-434-9553","contactType":"customer support"}],"openingHours":["Mo,Tu,We,Th,Fr,Sa,Su 09:00-17:00"],"description":"Regen Portal is a consulting and marketing firm for the regenerative medicine industry, from clinics to manufacturers and distributors. We have been in this industry since 2015, and we take on about five clients a year.","legalName":"Regen Portal LLC","foundingDate":"01\/01\/2025","numberOfEmployees":{"@type":"QuantitativeValue","value":"10"},"location":{"@id":"https:\/\/regenportal.com\/#place"}},{"@type":"WebSite","@id":"https:\/\/regenportal.com\/#website","url":"https:\/\/regenportal.com","name":"Regen Portal","alternateName":"regenportal.com","publisher":{"@id":"https:\/\/regenportal.com\/#organization"},"inLanguage":"en-US"},{"@type":"ImageObject","@id":"https:\/\/regenportal.com\/wp-content\/uploads\/2026\/09\/361-product-marketing-hctp-companies.png","url":"https:\/\/regenportal.com\/wp-content\/uploads\/2026\/09\/361-product-marketing-hctp-companies.png","width":"1250","height":"1250","caption":"361 product marketing as a walnut shelf of blank black archive boxes, one recess backlit green","inLanguage":"en-US"},{"@type":"BreadcrumbList","@id":"https:\/\/regenportal.com\/361-product-marketing-hctp-companies\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":"1","item":{"@id":"https:\/\/regenportal.com","name":"Home"}},{"@type":"ListItem","position":"2","item":{"@id":"https:\/\/regenportal.com\/blog\/","name":"Blog"}},{"@type":"ListItem","position":"3","item":{"@id":"https:\/\/regenportal.com\/category\/regulatory\/","name":"Regulatory"}},{"@type":"ListItem","position":"4","item":{"@id":"https:\/\/regenportal.com\/361-product-marketing-hctp-companies\/","name":"361 Product Marketing: 7 Clear Rules for HCT\/P Companies"}}]},{"@type":"WebPage","@id":"https:\/\/regenportal.com\/361-product-marketing-hctp-companies\/#webpage","url":"https:\/\/regenportal.com\/361-product-marketing-hctp-companies\/","name":"361 Product Marketing: 7 Clear Rules for HCT\/P Companies","datePublished":"2026-10-13T10:00:00-04:00","dateModified":"2026-10-13T10:00:00-04:00","isPartOf":{"@id":"https:\/\/regenportal.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/regenportal.com\/wp-content\/uploads\/2026\/09\/361-product-marketing-hctp-companies.png"},"inLanguage":"en-US","breadcrumb":{"@id":"https:\/\/regenportal.com\/361-product-marketing-hctp-companies\/#breadcrumb"}}]}
```